BeOne Medicines Director Exercises & Sells $11.3M in ADSs Ahead of Option Expiration

Executive Summary

On October 27, 2026, Dr. Xiaodong Wang, Director and Chair of the Scientific Advisory Board at BeOne Medicines Ltd. ($ONC), executed an option exercise and full sale of the resulting equity under a pre-established Rule 10b5-1 plan.

Transaction Details

• Derivative Exercise: Dr. Wang exercised options to acquire 403,364 Ordinary Shares (equivalent to 31,028 American Depositary Shares, where 1 ADS = 13 Ordinary Shares) at an exercise price of $2.84 per Ordinary Share ($36.90 per ADS). The options were set to expire on November 15, 2026.
• Open Market Dispositions: Dr. Wang sold all 31,028 ADSs on the open market in multiple tranches across a price range of $355.08 to $366.45 per ADS, yielding an aggregate gross value of approximately $11,262,131 (weighted average price of ~$362.97 per ADS).
• Rule 10b5-1 Plan: The transactions were conducted pursuant to a Rule 10b5-1 plan adopted on June 9, 2026.

Holdings Context

While Dr. Wang disposed of all 31,028 ADSs acquired via the option exercise, his broader equity stake remains substantial. Following the transactions, he continues to hold:

• Directly: 4,588,113 Ordinary Shares
• Indirectly: 4,978,213 Ordinary Shares held across a family trust, Wang Investment LLC, and his spouse.

Market & Governance Impact

Because this transaction represents an exercise and liquidation of options approaching expiration (November 15, 2026) under a pre-arranged 10b5-1 plan, it constitutes routine executive compensation realization rather than a discretionary directional bet on the company's valuation.